Peptris Technologies
AI-Powered Drug Discovery for Faster & Cost-Effective Therapeutics
Ready to see Peptris Technologies in action?
Book a personalized demo with our team.
Overview
Peptris’ proprietary AI platform combines unsupervised learning, generative AI, and neural network models to explore chemical space and predict biologically active compounds with improved properties. The technology accelerates the identification of novel chemical entities and repurposes existing drugs for new indications, helping cut time and costs in early drug discovery phases. Operating virtually, the company partners with CROs and biotech firms to advance candidates into preclinical validation. Peptris has a pipeline spanning oncology, inflammation, and rare diseases, and its lead asset PEPR-124 has been licensed for development in Duchenne Muscular Dystrophy.
Who It's For
Pharmaceutical R&D teams, Biotech companies, Drug discovery researchers, Academic research institutions
Key Strengths
AI-enabled molecule designAccelerated preclinical discoveryReduced experimental costsNovel & repurposed drug discovery focus
Primary Use Cases
AI-powered novel molecule generation
Repurposing approved drugs for new indications
Rescue of clinical candidates with unmet potential
Preclinical candidate optimization
Technical Specifications
Supported AI Models
Proprietary AIGenerative ML
Deployment Methods
Cloud
Supported Languages
English
Company Information
Location
Bengaluru, India
Company Size
2-10 employees